Citadel Advisors’s Cumberland Pharmaceuticals CPIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$476K Buy
73,391
+56,748
+341% +$272K ﹤0.01% 9975
2026
Q1
$54.1K Sell
16,643
-5,314
-24% -$20.5K ﹤0.01% 12375
2025
Q4
$87.4K Sell
21,957
-19,488
-47% -$57.8K ﹤0.01% 11739
2025
Q3
$129K Sell
41,445
-32,961
-44% -$110K ﹤0.01% 11646
2025
Q2
$249K Buy
74,406
+48,592
+188% +$230K ﹤0.01% 10216
2025
Q1
$109K Buy
+25,814
New +$107K ﹤0.01% 11337
2024
Q3
– Sell
-834
Closed -$1.15K – 14336
2024
Q2
$1.28K Sell
834
-2,788
-77% -$4.38K ﹤0.01% 13842
2024
Q1
$6.08K Buy
3,622
+87
+2% +$174 ﹤0.01% 13700
2023
Q4
$6.15K Sell
3,535
-2,398
-40% -$4.39K ﹤0.01% 13372
2023
Q3
$11.2K Sell
5,933
-13,776
-70% -$23.1K ﹤0.01% 13019
2023
Q2
$29K Sell
19,709
-1,624
-8% -$2.8K ﹤0.01% 12391
2023
Q1
$41.6K Sell
21,333
-7,789
-27% -$18.5K ﹤0.01% 12391
2022
Q4
$65.5K Buy
+29,122
New +$67.6K ﹤0.01% 11792
2021
Q4
– Sell
-12,021
Closed -$32K – 13883
2021
Q3
$32K Buy
+12,021
New +$35.7K ﹤0.01% 13550
2021
Q2
– Sell
-17,005
Closed -$52K – 13738
2021
Q1
$52K Buy
+17,005
New +$55.3K ﹤0.01% 12883
2016
Q3
– Sell
-12,895
Closed -$58K – 7285
2016
Q2
$58K Buy
12,895
+1,671
+15% +$7.66K ﹤0.01% 6374
2016
Q1
$50K Buy
+11,224
New +$53.5K ﹤0.01% 6248
2014
Q2
– Sell
-14,475
Closed -$65K – 7988
2014
Q1
$65K Buy
+14,475
New +$68.9K ﹤0.01% 6549
2013
Q3
– Sell
-38,959
Closed -$199K – 6744
2013
Q2
$199K Buy
+38,959
New +$194K ﹤0.01% 4677

Other funds holding CPIX

Citadel Advisors's CPIX Position: Q2 2026 in Review

Citadel Advisors increased its Cumberland Pharmaceuticals (CPIX) stake by 341% in Q2 2026, buying an estimated $272K and bringing the position to 73,391 shares worth $476K. The position accounts for ﹤0.01% of the portfolio, ranked #9975.

Citadel Advisors first reported a position in CPIX in Q2 2013 and has held it in 19 quarters since. 32 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.

  • Citadel Advisors held 73,391 shares of Cumberland Pharmaceuticals worth $476K as of Q2 2026.
  • Citadel Advisors bought 56,748 Cumberland Pharmaceuticals shares in Q2 2026, an estimated $272K.
  • Cumberland Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9975 holding.
  • Citadel Advisors first reported a position in Cumberland Pharmaceuticals in Q2 2013 and has held it in 19 quarters since.
  • 32 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.